Inside the Lemonaid Health Buy: Kyle Pretsch on Bambu Ventures’s Bold Play
Bambu Ventures's Kyle Pretsch dives into Lemonaid’s $10M buyout, down from 23andMe’s $400M price tag, and what’s next after Chrome Co.’s dramatic pivot.
More Videos
Inside Nvidia’s Record Quarter and the Global AI Arms Race
Ray Wang of Constellation Research breaks down Nvidia’s blockbuster earnings and the future of the AI chip race.
How Xometry Is Transforming the Future of Manufacturing
Randy Altschuler, CEO of Xometry, discusses AI, automation and the rise of on-demand manufacturing.
The Billion-Dollar AI Breakup: Inside Musk’s Failed War Against OpenAI
Andrew Nusca, Editorial Director at Fortune, breaks down how Musk’s failed $150 billion lawsuit could reshape AI governance.
SpaceX, OpenAI and Anthropic Set the Stage for an IPO Frenzy
Jim Neesen of Connor Group discusses the AI-driven IPO boom, SpaceX, OpenAI, Anthropic and whether Wall Street can sustain the hype.
Why the Beijing Summit Could Reshape the Future of AI
Politico’s Aaron Mak breaks down the Trump-Xi Beijing summit, AI competition, semiconductor tensions and what it means for global tech.
Inside the Clarity Act: Can Washington Finally Bring Order to Crypto?
The Clarity Act could reshape U.S. crypto regulation by defining digital assets and resolving SEC–CFTC jurisdiction. Paul Grewal of Coinbase weighs in.
